← All trials
NCT06778967
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 7, 2025
- Primary completion
- Aug 28, 2026
- Completion date
- Dec 11, 2026
- First posted
- Jan 16, 2025
- Last posted
- Jan 16, 2025
- Enrollment
- 1100
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gan and Lee Pharmaceuticals, USALead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.